The $37bn Bill & Melinda Gates Foundation, the world’s largest philanthropic organisation, reportedly plans to take equity stakes in up to a dozen biotech companies this year in a quasi-corporate venturing model, following moves by peers including Wellcome Trust and Novo. Trevor Mundel, the Gates Foundation’s recently appointed head of global health, told news provider…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
